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Physician-modified endovascular grafts for the
treatment of elective, symptomatic, or ruptured
juxtarenal aortic aneurysms
Benjamin W. Starnes, MD, FACS, Seattle, Wash
Objective: To determine if a physician-modified endovascular graft (PMEG) is a safe and effective method of treating
juxtarenal aortic aneurysms in patients considered to be unsuitable for open surgical repair.
Methods: A retrospective, nonrandomized, single institution evaluation of the safety and efficacy of physician modification
of a currently Food and Drug Administration-approved device (Zenith Flex; Cook Inc, Bloomington, Ind) to preserve
branch vessels when used in the treatment of patients with elective, symptomatic, or ruptured juxtarenal aortic aneurysms.
Results: Forty-seven consecutive patients underwent fenestrated endovascular repair using PMEG over a 3-year period.
Thirty-eight patients (80%) were symptomatic or had rapid aneurysm expansion. Eighty-five percent of patients were
American Society of Anesthesiologist category III or IV. Eight-two fenestrations were created for 58 renal arteries, 16
superiormesenteric arteries, three celiac arteries, and the rest accessory vessels.Mean follow-upwas 607 days, with a range
of 425 to 1460 days. Mean contrast usage and fluoro time were 98 mL and 48 minutes. Technical success rate was 98%, and
freedom from aneurysm-related death was 98%. There were six complications (13%). Three (6%) were access related, and three
(6%)were procedure related and included one stroke, one case of renal failure, and one branch artery dissection.On follow-up,
six patients (13%) had endoleak.Therewas one type 1 endoleak andfive type 2 endoleaks. In-hospital and30-daymortalitywas
2%, with one patient expiring due to aspiration on the ward after successful endovascular repair. Two patients died during
follow-up; one at 58 days due to cessation of dialysis and one at 485 days due to stent graft migration and occlusion of the
superior mesenteric artery. There were two deaths in the first year, one in the second year, and zero in the most recent year of
experience. One patient with endoleak (2%) had aneurysm sac expansion at 1 year requiring secondary intervention.
Conclusions: PMEG is a safe and effective alternative for treating patients with juxtarenal aneurysms who have no other
alternatives for repair. Longer-term follow-up is needed to assess the durability of repair and potential for device-related
complications. ( J Vasc Surg 2012;56:601-7.)
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sEndovascular treatment of aortic pathology has be-
comemainstream and standard practice inmost institutions
for the treatment of patients with infrarenal aortic aneu-
rysms who are anatomically suitable for repair. Themajority
of patients who are not eligible for endovascular repair
typically harbor proximal aortic neck deficiencies. Reasons
for ineligibility include short proximal necks and juxtarenal
aneurysms. In clinical trials in the United States and in
other countries, fenestrated technology has been used to
extend the applicability of endovascular techniques to more
patients who would be deemed ineligible for standard
infrarenal bifurcated repair.1-7 These grafts are customized
to the patient and typically require between 6 and 12 weeks
to manufacture. Patients presenting with symptomatic and
ruptured juxtarenal aortic aneurysms would therefore be
ineligible for these techniques without an “off-the-shelf”
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doi:10.1016/j.jvs.2012.02.011ption. The objective of this study was to determine if an
mmediate physician-modified endovascular graft (PMEG)
s a safe and effective method for treating juxtarenal aortic
neurysms in patients deemed unsuitable for traditional
pen surgical repair or who, while presenting in an urgent
ashion, cannot wait for entry into a clinical trial.
ETHODS
This study was approved by the Institutional Review
oard at the University of Washington and was a retrospec-
ive review of a consecutively logged, nonrandomized eval-
ation of the safety and efficacy of PMEG. This entire study
as conducted at Harborview Medical Center in Seattle,
ashington, and involved customized device modification
f a commercially available and Food and Drug Adminis-
ration (FDA)-approved aortic stent graft (Zenith Flex
evice; Cook Inc, Bloomington, Ind). Patients were cho-
en based upon presentation with a juxtarenal aortic aneu-
ysm and with no alternative for open repair.
During the 3-year period of study and as a point of
eference, there were 533 aortic procedures done at Har-
orview Medical Center. Abdominal aortic procedures ac-
ounted for 352 of these procedures. Overall, there were
42 nonruptured abdominal aortic aneurysms, of which 41
ere treated using an open approach and 201 using an
ndovascular approach. One hundred ten patients pre-
ented with a ruptured abdominal aortic aneurysm during
he study period, of which 32 were treated using an open
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September 2012602 Starnesapproach and 78 using an endovascular approach. Includ-
ing both nonruptured and ruptured juxtarenal aortic aneu-
rysms, there were a total of 74 patients undergoing open
repair versus the 47 patients who serve as the basis for this
report on PMEG.
A computed tomographic angiogram from a represen-
tative patient is shown in Fig 1 demonstrating a short
infrarenal aortic neck and a large juxtarenal aneurysm. Three-
dimensional reconstruction imaging software (Aquarius;
Tera-Recon, Foster City, Calif) was routinely used for
preoperative planning to ensure precise placement of aortic
fenestrations in “clock face” positions for branch vessel
preservation.
Device preparation. All operative procedures were
performed concurrently with back table device modifica-
tion while the patient was being prepared for surgery. The
device was chosen according to standard instructions for
use sizing guidelines, and a routine aortic oversizing of 10%
to 15% for the main body graft was utilized. The bifurcated
graft was unsheathed on a separate table, and a sterile
marking pen was used to mark the location of the fenestra-
tions based on both length and clock face measurements
that had been previously determined with reconstruction
imaging software. Minor adjustments were made in local-
ization of the fenestrations to allow for maximum usage of
strut-free fenestrations when possible. When this was not
possible and multiple fenestrations were required, struts
within fenestrations were preferentially avoided for the
renal arteries. An ophthalmic Bovie cautery device
(Medtronic,Minneapolis, Minn) was used to carefully burn
the Dacron fabric to create all fenestrations and thus avoid
fabric fraying. Gold, 15-mm Amplatz Gooseneck Snares
Fig 1. A computed tomographic angiogram from a repr
and a large juxtarenal aneurysm. A, Coronal computed to
from a short aortic neck immediately cephalad to a large(ev3 Endovascular Inc, Plymouth,Minn) were then used to teinforce all fenestrations. These were hand-sewn into place
sing 4-0 Prolene suture in a 720 degree running fashion
Fig 2). A typical final PMEG device is depicted in Fig 3.
iameter-reducing ties were then used to constrain the
evice along its posterior border (opposite the superior
esenteric artery [SMA] and or celiac fenestration at 6
’clock) by rerouting the existing proximal trigger wire
hrough and through the graft material at the midportion
f each of the top two Z stents. The constraining ties were
hen tied down into place over the trigger wire. The bare
tent was then reconstrained in the top cap, and the entire
raft wetted with heparinized saline and then reloaded into
ative patient demonstrating a short infrarenal aortic neck
raphic angiogram image. B, Left renal artery originating
renal aneurysm (C).
ig 2. Gold, 15-mmAmplatz Gooseneck Snares (ev3, Plymouth,
inn) were then used to reinforce all fenestrations. These were
and sewn into place using 4-0 Prolene suture in a 720 degree
unning fashion.esent
moghe existing sheath.
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Volume 56, Number 3 Starnes 603PMEG procedural details. The majority of these
procedures were performed in a modern angiography suite
utilizing a Philips Allura Xper FD 20/10 system (Philips
Healthcare, Amsterdam, The Netherlands). Three cases
were for rupture and were performed in a standard operat-
ing room with a portable imaging unit (OEC 9900 Elite;
General Electric, Chalfont St Giles, United Kingdom).
Common femoral access was almost always achieved in a
standard percutaneous fashion and the stent graft delivered
up into position near the visceral vessels. A contrast aorto-
gramwith 10mL of dilute contrast injected at 25mL/s was
performed with the PMEG in place to mark the visceral
vessels (Fig 4). Proper orientation of the graft (SMA ante-
rior) was confirmed by rotating the graft clockwise under
fluoroscopy and confirming that the SMA fenestration
moved from left to right instead of right to left, which
would denote a posterior orientation of the SMA fenestra-
tion. The graft was then carefully deployed down to the
opening of the contralateral limb. The contralateral limb
was then selected, and, typically, an 18 to 20 Fr sheath
inserted into the contralateral limb over a stiff wire under
direct fluoroscopic visualization. Double 6 or 7 Fr Ansel
sheaths (Cook Inc) were used through separate punctures
Fig 3. A typical physician-modified endovascular graft
(PMEG) prior to device repackaging (A). Fenestrations for the
superior mesenteric artery (SMA) (struts present) and left and
right renal arteries (strut-free) were created for this particular
patient. B, Rerouting of the trigger wire to allow for placement of
graft constraining ties.in this blank sheath to individually select the renal arteries ihile maintaining stability of the PMEG device. Once the
enal arteries were completely selected with each 6 or 7 Fr
heath, diameter-reducing ties were freed by pulling the
roximal trigger wire out, then the top cap was released and
he main body deployed. At this time, the remainder of the
ain body device was deployed, the top cap retrieved, and
CODA balloon (Cook Inc) was used to seat the proximal
ortion of the graft in the zone of the visceral aortic stent
raft segment (Fig 5). The renal arteries were then individ-
ally stented with appropriately sized iCAST stents (Atrium
SA, Hudson, NH), and the stents were flared proximally
nto the aortic stent graft using either 8 or 9 mm standard
ngioplasty balloons. The remainder of the procedure in-
olved standard placement of docking limbs to the level of
ach iliac bifurcation and seating of the stent graft overlap
nd seal zones with a molding balloon (CODA, Cook Inc).
completion aortogram was performed at the completion
f each procedure (Fig 6).
ESULTS
A total of 47 patients with asymptomatic, symptomatic,
r ruptured juxtarenal aortic aneurysms were treated be-
ween April 2007 and April 2010. Thirty-eight patients
80%) were either symptomatic (abdominal pain or aneu-
ysms that were tender to palpation) or had documented
apid aneurysm expansion as evidenced by an increase in
neurysm diameter of 0.5 cm in the previous 6 months or
.0 cm in the previous year. Forty patients (85%) were
merican Society of Anesthesiology (ASA) category 3 or 4.
ean follow-up was 607 days, with a range of 425 to 1460
ays. Follow-up imaging of the procedure described above
ig 4. Contrast aortography demonstrating the origins of all four
isceral vessels with the physician-modified endovascular graft
PMEG) device in situ prior to deployment.s depicted in Fig 7.
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September 2012604 StarnesDemographics and patient characteristics are listed in
Table I. Nearly half of the patients had a history of coronary
artery disease, nearly one-third had a history of congestive
heart failure, and one-third had chronic obstructive pulmo-
nary disease. Mean age was 75 years (range, 54-87 years),
mean aneurysm diameter was 5.8 cm, and mean ASA class
was 3. Three patients presented with a ruptured juxtarenal
aortic aneurysm and were ASA category 4E.
Overall, 82 fenestrationswere created for 58 renal arteries,
16 SMAs, three celiac arteries, and five accessory renal arteries.
Procedural details are listed in Table II. Mean operative time
was 185minutes (range, 66-349minutes), mean fluoroscopy
time was 48 minutes (range, 4.1-119.2 minutes), and mean
contrast usage was 98 mL (range, 30-204 mL). Estimated
blood loss was, on average, 119mL (range, 50-750mL), and
general anesthesia was utilized in 94% (n  44) of cases.
Technical success rate was 98%, and freedom from aneurysm-
Fig 5. Physician-modified endovascular graft (PMEG)
the renal fenestrations and a sheath advanced into the le
sheaths securely in place. C, Stent grafting and subseque
Fig 6. Completion aortogram demonstrating absence of en-
doleak and good alignment of all three visceral vessel fenestrations.related death was 98%.Mean length of stay was 4 days (range, d-30 days). Graft modification times averaged 48minutes but
ere not recorded on all patients.
Overall, there were six complications in this series
13%). Three were access site-related (6%), and three (6%)
ere procedure-related, including one stroke, one perma-
ent renal failure, and one renal artery dissection. Six
atients had endoleaks (13%). There was one type 1 en-
oleak that required intervention and subsequent repair.
f the five type 2 endoleaks, one required secondary inter-
ention due to aneurysm sac growth at 1 year.
In-hospital and thirty-day mortality was 2% (n  1).
his particular patient had an underlying diagnosis of mul-
iple myeloma and had a “DoNot Resuscitate” order in her
edical record. She unfortunately aspirated on the hospital
ard on postoperative day 2, and her wishes for no resus-
itation were abided by. Two patients died during follow-
p. One patient died at 58 days due to voluntary cessation
f dialysis, and one patient died at 485 days due to en-
ograft migration and SMA occlusion. The latter patient
as an 87 year old who presented with a symptomatic
uxtarenal aneurysm, and the fenestrations were not
tented. This was early on in our experience and led to a
andatory policy of at least one visceral artery stent per
MEG procedure to mitigate the risk of stent graft migra-
ion. Kaplan-Meier survival curves for the entire cohort are
epicted in Fig 8.
ISCUSSION
Endovascular repair of aortic aneurysmal disease has
ecome a mainstay of treatment in most modernized coun-
ries. The paravisceral segment of the aorta has become a
ocus of improved device design in order to apply advanced
ndovascular technologies to more and more patients who
ould be deemed “unsuitable” candidates based on ana-
omic criteria. These improved device designs have in-
luded both branched and “fenestrated” (fenestra: Latin
window”) constructs. There exists a certain degree of
ariability in the origins of the visceral vessels in humans,
nd hence a customized design has been promoted with
ach device custom-made for any specific patient. As one
ight imagine, any device customization involves a time
dure. A, Both renal arteries have been selected through
al artery. B, Seating of the proximal graft with the renal
ring of the renal artery stents.proce
ft renelay between patient sizing, the manufacture of the de-
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Volume 56, Number 3 Starnes 605vice, and the actual implantation event. Currently, this
process takes, in the best of circumstances, 8 to 12 weeks.
These emerging devices are widely available in countries
outside the United States and unfortunately only in select
centers within the United States under an umbrella of an
investigational trial.
The concept of fenestrated stent grafting was first de-
scribed by Park et al in a canine model,8 and early experi-
ence in humans was described by Chuter et al in 1999.9
There have been several single center2,4,5,7 and few multi-
center trials1,3,6 evaluating the use of fenestrated en-
dografts in patients with juxtarenal aneurysms. These stud-
ies all share remarkable results of low mortality,
Fig 7. Six-month follow-up im
Table I. Demographics and patient characteristics
Demographics N (%)
Male 27 (57.4)
Coronary artery disease 23 (48.9)
Congestive heart failure 13 (27.7)
Hypertension 45 (95.7)
Chronic obstructive pulmonary disease 16 (34.0)
Diabetes mellitus 10 (21.3)
Hyperlipidemia 34 (72.3)
Table II. Physician-modified endovascular graft
procedure details
Procedural details Mean or % (range)
Operative time 185 minutes (66-349 minutes)
Fluoroscopy time 48 minutes (4.1-119.2 minutes)
Contrast usage 98 mL (30-204 mL)
Estimated blood loss 119 mL (50-750 mL)
General anesthesia 94%averaging 1% to 2% at 30 days, and low rates of branch bessel occlusion. In all but one of these studies, there
ere zero aneurysm-related deaths. The only aneurysm-
elated death was in a patient who experienced massive
leeding during redo surgery for infection.4 In an at-
empt to offer this technique to some patients who have
o other options for aneurysm repair, some authors have
ttempted to modify existing stent grafts.10,11 The du-
ability of this approach has yet to be vetted and is the
asis for this report on our initial experience. Until an
off-the-shelf” device is available, patients with rapidly
xpanding, symptomatic, or ruptured juxtarenal aneu-
ysms who are poor candidates for open surgical repair
ave limited options other than immediate physician
odification or PMEG.
Our results with PMEG compare favorably with the
xisting literature. PMEG was associated with a 2% 30-
ay mortality in a single patient who died of an aspiration
vent on the first postoperative day. Immediately appar-
nt when analyzing our data is that our average number
f fenestrations per patient is 1.75 compared with two to
hree in other studies.1-3,6 We began this program in
pril 2007, treating patients with discrepant renal arter-
es and a single fenestration for one low-lying renal
rtery. After a dozen or so patients, we began to reach
igher into more normal aorta, realizing that the ability
o seal was better when the seal zone was in the healthiest
ortion of aorta. This required more precise planning
nd incorporation of between two and four fenestrations
er procedure.
There exists an obvious legal risk to modifying an
xisting FDA-approved medical device that involves prod-
ct liability. Once a physician decides to modify a device
hat has been intended for other indications, the manufac-
urer can deny any responsibility for a malfunctioning de-
ice, and the physician who chose to modify the device
in patient depicted in Figs 1-6.ecomes the responsible party. Due to ethical and legal
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September 2012606 Starnesimplications of performing device modification without an
Investigational Device Exemption (IDE), in April of 2010,
we elected to perform an external review of our experience
(the basis of this report) under an Institutional Review
Board (IRB)-approved protocol at the University of Wash-
ington. We then used these data to approach the FDA with
a formal IDE application to prospectively study PMEG for
patients with juxtarenal aneurysm pathology. In January
2011, wewere given full approval from the FDA to conduct
this IDE at the University of Washington. We began en-
rolling patients into this IDE in March 2011 and currently
have performed 19 successful PMEGprocedures. The prac-
tice of PMEG is now being attempted at more and more
centers in the United States outside of a formal IDE. It is
the author’s opinion that PMEGwill definitely play a future
role in the management of these complex patients. In fact,
in some centers, it may play the only role due to compara-
tive effectiveness and low cost if it can be shown to be just
as safe and effective as commercial custom devices, which
require extensive manufacture times and may be more
costly.
It should be noted that fenestrated endografting in and
of itself has not been validated in a prospective, randomized
fashion. Mortality rates for open repair of juxtarenal aneu-
rysms are often quoted to be quite low in high-volume
centers, which does not accurately reflect the true operative
Fig 8. Kaplan-Meier survival curves depicting cumula
physician-modified endovascular graft (PMEG).mortality rate in most centers. What is required are accurate Wulti-center studies assessing the current true outcomes of
pen juxtarenal aneurysm repair to benchmark against cur-
ent fenestrated approaches.
ONCLUSIONS
In conclusion, PMEG seems to be a safe and effective
lternative for treating patients with asymptomatic, symp-
omatic, and ruptured juxtarenal aortic aneurysms who
ave limited alternatives for repair. Longer-term follow-up
s needed to determine the durability of this approach and
he potential for device-related complications. In the fu-
ure, there must be the availability of “off-the-shelf” en-
ografts or the capability of immediate modification of
urrently available stent grafts to treat patients with symp-
omatic or ruptured aortic aneurysms. It is the author’s
pinion that immediate device modification should be per-
ormed only at centers completely familiar with all ad-
anced endovascular aortic and visceral artery techniques
nd a high volume (at least 30-50 patients per year or two
o four per month) of these fenestrated procedures.
This work would not have been possible without the
fforts of Billi Tatum, RN, Research Coordinator at the
niversity of Washington, Claudette Cooper, RN, and
ohn Blanchard,MHA,Director of Regional Vascular Cen-
er, Harborview. PMEG is a trademark of the University of
survival for the entire cohort of patients undergoingtiveashington.
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